Allgemeinmedizin up2date, Journal Year: 2022, Volume and Issue: 03(02), P. 89 - 89
Published: May 1, 2022
Im Rahmen der Behandlung von Patienten mit Dyslipidämie und einem erhöhten kardiovaskulären Risiko stellen Statine die zentrale Behandlungsoption dar. Leider geht Einsatz dieser Substanzen einer geringen Therapietreue hohen Therapieabbruchrate einher. J. T. Reston et al. haben Interventionen auf ihre Eignung hin überprüft, bei für kardiovaskuläre Erkrankungen Adhärenz zu verbessern.
European Heart Journal, Journal Year: 2023, Volume and Issue: 44(39), P. 4043 - 4140
Published: Aug. 25, 2023
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical judgment, as well determination implementation preventive, diagnostic strategies; however, do override, way whatsoever, individual responsibility make appropriate accurate decisions each patient's condition consultation with that patient and, where necessary, caregiver.Nor exempt from taking full updated competent order manage case light scientifically accepted data pursuant respective ethical professional obligations.It also professional's verify applicable rules regulations relating drugs devices prescription.
Language: Английский
Citations
698
Canadian Medical Association Journal, Journal Year: 2023, Volume and Issue: 195(21), P. E729 - E738
Published: May 28, 2023
The role of statin therapy in the development kidney disease patients with type 2 diabetes mellitus (DM) remains uncertain. We aimed to determine relationships between initiation and outcomes DM.
Language: Английский
Citations
32
Journal of Diabetes and its Complications, Journal Year: 2025, Volume and Issue: unknown, P. 109040 - 109040
Published: April 1, 2025
Language: Английский
Citations
0
Journal of Ethnopharmacology, Journal Year: 2022, Volume and Issue: 290, P. 115101 - 115101
Published: Feb. 11, 2022
Language: Английский
Citations
17
International Journal of Environmental Research and Public Health, Journal Year: 2023, Volume and Issue: 20(10), P. 5878 - 5878
Published: May 19, 2023
Poor adherence to chronic disease treatment may seriously compromise the effectiveness of therapy, characterizing itself as a critical element for population’s health, both from point view quality life and health economics. The causes low are many can depend on patient, physician healthcare system. Low dietary recommendations lipid-lowering drug therapy hypercholesterolemia is widespread phenomenon that strongly limit great advantages serum lipid reduction strategies in primary secondary cardiovascular prevention. Many patients discontinue treatment, decreases with time. Increasing therapeutic have much greater impact population than any other advance. There numerous increase according behavior change theories. They concern doctor patient. Some must be implemented at time prescription, others later during follow-up. active role patient decision shared definition LDL cholesterol targets paramount importance. aim this narrative review summarize evidence current levels strategies, lack adequate possible physician-applicable improve it.
Language: Английский
Citations
10
JAMA Cardiology, Journal Year: 2022, Volume and Issue: 8(1), P. 74 - 74
Published: Nov. 23, 2022
Statin-associated muscle symptoms (SAMS) are common and may lead to discontinuation of indicated statin therapy. Observational studies suggest that vitamin D therapy is associated with reduced intolerance, but no randomized have been reported.To test whether supplementation was prevention SAMS a reduction discontinuation.Men 50 years or older women 55 older, free cancer cardiovascular disease, were enrolled in randomized, placebo-controlled, double-blind clinical trial supplementation. Participants who initiated after randomization surveyed early 2016. The data analyzed 2022.Daily cholecalciferol (2000 international units) placebo assessment prescriptions during follow-up.Muscle pain discomfort lasting several days (primary outcome) due (secondary outcome).Statins by 1033 D-assigned participants 1050 placebo-assigned participants; mean (SD) age 66.8 (6.2) 49% women. Over 4.8 follow-up, reported 317 (31%) assigned 325 (31%). adjusted odds ratio (OR) 0.97 (95% CI, 0.80-1.18; P = .78). Statins discontinued 137 (13%) 133 an OR 1.04 0.80-1.35; These results consistent across pretreatment 25-hydroxy levels (interaction value .83). Among less than 20 ng/mL, 28 85 (33%) 33 95 (35%). For those 30 ng/ml, 88 330 vitamin-D (27%) 96 323 (30%).Vitamin did not prevent reduce discontinuation. levels.ClinicalTrials.gov Identifier: NCT01169259.
Language: Английский
Citations
16
Journal of Gastroenterology and Hepatology, Journal Year: 2022, Volume and Issue: 37(5), P. 946 - 953
Published: March 2, 2022
Considering the inconsistent findings of research into associations between serum levels liver enzymes (alanine aminotransferase [ALT], aspartate [AST], and gamma-glutamyltransferase [GGT]) mortality among elderly people, we aimed to investigate ALT, AST, GGT, De-Ritis ratio (DRR, defined as AST/ALT) all-cause or cause-specific US people using National Health Nutrition Examination Surveys data.We included 6415 participants (≥ 65 years). Exclusion criteria positive test for hepatitis B virus, C human immunodeficiency virus infection at baseline. Multivariable-adjusted Cox regression models calculating hazard ratios (HR) 95% confidence intervals were developed each enzyme measures.All-cause cumulative was 33.8%, which 23.8% cardiovascular disease (CVD) deaths, 15.6% cancer 60.6% other cause deaths. Adjusted found increased risk low ALT (HR: 1.70), AST 1.13), high GGT 1.25), DRR 1.68). Low predicted CVD mortality. 1.91), 1.16), 1.40), 1.76) mortality.Low associated with All measures in population. Further studies may validate these populations.
Language: Английский
Citations
15
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, Journal Year: 2022, Volume and Issue: 42(5), P. 428 - 438
Published: April 7, 2022
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also known as "statins" are considered first-line pharmacologic therapy for reducing low-density lipoprotein cholesterol (LDL-C). They have been demonstrated efficacy in a variety of patients populations to reduce atherosclerotic cardiovascular disease (ASCVD) risk. Like any therapy, however, they not without possible adverse effects that can lead discontinuation, thus leading loss benefit. most common side effect related statin impacting compliance is musculoskeletal related, commonly referred statin-associated muscle systems (SAMS). While the overall incidence relatively low, consequences nonadherence negative impact on patient care. Therefore, it important healthcare providers understand risk factors, how diagnose, and manage this unfortunate order optimize
Language: Английский
Citations
15
Expert Review of Cardiovascular Therapy, Journal Year: 2023, Volume and Issue: 21(6), P. 423 - 435
Published: May 22, 2023
Statins are the cornerstone for atherosclerotic cardiovascular disease risk reduction with recognized efficacy in primary and secondary prevention. Despite this, they remain underutilized due to concerns regarding adverse effects. Statin-associated muscle symptoms (SAMS) most frequent cause of medication intolerance discontinuation a prevalence estimated at 10%, regardless causality, consequence increased outcomes.This clinical perspective reviews recent developments mechanisms underlying pathogenesis statin myopathy, role nocebo effect perception intolerance, explores diverse components endorsed by international societies establishing syndrome. Non-statin drug alternatives that reduce low-density lipoprotein-cholesterol also discussed, emphasis on therapies established effects outcomes.Ultimately, patient-centered approach managing SAMS is proposed optimize tolerability, achieve guideline-recommended therapeutic goals improve outcomes.
Language: Английский
Citations
7
Current Opinion in Cardiology, Journal Year: 2021, Volume and Issue: 36(4), P. 487 - 493
Published: April 29, 2021
Purpose of review Hypercholesterolemia is a major risk factor for cardiovascular diseases. Administration statins represents the cornerstone prevention and treatment disease, with demonstrated long-term safety efficacy. This aims to revisit statin intolerance mechanisms, as well discuss new data therapeutic options. Recent findings Although are tolerated, myopathy other adverse effects challenging problem, being main reason poor adherence failure in lowering risk. Statin subject ongoing research, these drugs widely used. There alternative options if emerges, that is, dose, intermittent dosages, and/or combining drugs, such ezetimibe, proprotein convertase subtilisin–kexin type 9 inhibitors, bempedoic acid, angiopoietin-like 3 protein nutraceuticals. If even lowest dose cannot be nonstatin regimen recommended reduce LDL cholesterol levels. Summary Treatment include combinations lower lipid-lowering regimens or only presence complete intolerance. New hypolipidemic therapies address gene editing emerging, may prove useful future.
Language: Английский
Citations
17